CODX
FDA paperwork, now with extra paperwork
Co-Diagnostics says it has submitted a dual 510(k) premarket notification, plus a concurrent CLIA Waiver by Application, for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test. Translation: the company is trying to get its test cleared for use in decentralized point-of-care settings, where speed and convenience matter more than a big fancy central lab.
Why investors are watching
This isn’t revenue in the bank yet — it’s a regulatory checkpoint. But for diagnostics names, clearing FDA hurdles can be the difference between “interesting science project” and “actual product people can use.”
The company says the filing follows completion of the clinical and analytical performance studies supporting the test, which is the sort of line investors like to hear because it suggests the package is at least assembled and headed to the agency.
The big picture
If this gets approved, Co-Diagnostics could have a more compelling case for its Co-Dx PCR Pro platform in real-world settings like clinics, urgent care, and other decentralized sites. Big picture: in diagnostics, the paper trail is the gatekeeper, and today’s news says CODX just walked up to the gate.